ProKidney Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $377.6M
- Price
- $1.84
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.10%
- Volume
- 1.0M
Quote data as of 5:26 AM ET
About
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Quick stats
Shares outstanding205.2M
Computed float88.1M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001850270
Websitehttps://www.prokidney.com
AI Summary
AI-generated1mo agominorbullishexecutive changeProKidney Appoints Kenneth Locke as Chief Technical Officer
ProKidney appointed Kenneth Locke as Chief Technical Officer to lead technical strategy and manufacturing operations.
Locke brings extensive experience from Carisma Therapeutics, Celgene, and Novartis, specifically in scaling cell therapy platforms and managing CMC functions.
The hire coincides with the company’s approach toward a pivotal Phase 3 topline readout in Q2 2027 for its lead asset rilparencel.